Clinical trial
A Phase 2, Randomized, Observer-Blind, Multicenter Study to Evaluate the Immunogenicity and Safety of Several Doses of Antigen and MF59 Adjuvant Content in a Monovalent H5N1 Pandemic Influenza Vaccine in Healthy Pediatric Subjects 6 Months to < 9 Years of Age
NCT04669691 is registered in ClinicalTrials.gov with Seqirus as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- A Phase 2, Randomized, Observer-Blind, Multicenter Study to Evaluate the Immunogenicity and Safety of Several Doses of Antigen and MF59 Adjuvant Content in a Monovalent H5N1 Pandemic Influenza Vaccine in Healthy Pediatric Subjects 6 Months to < 9 Years of Age
- Lead sponsor
- Seqirus
- Phase
- Phase 2
- Overall status
- Completed
- Start date
- December 19, 2020
- Completion date
- April 15, 2022
- Enrollment
- 420 (actual)
- Sites
- 7
Conditions
As the registry lists them; a condition with its own page is linked.